Rhythm Pharmaceuticals

Last Updated:



quotes and stock data delayed 15 minutes



Burn Rate (Qtr)


Company Profile

Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity. The company recently announced topline results from pivotal Phase 3 clinical trials in POMC deficiency obesity and LEPR deficiency obesity. Rhythm is also conducting a pivotal Phase 3 trial in Bardet-Biedl syndrome and Alström syndrome. The company is leveraging the Rhythm Engine -- comprised of its Phase 2 basket study in additional rare genetic disorders of obesity, TEMPO Registry, GO-ID genotyping study and Uncovering Rare Obesity program -- to improve the understanding, diagnosis and potentially the treatment of these disorders. For healthcare professionals, visit www.UNcommonObesity.com for more information.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

IMCIVREE™ (setmelanotide)

Proopiomelanocortin deficiency (POMC) deficiency obesity

Quarterly Sales (Approved)

March 5, 2021 (Est)

IMCIVREE™ (setmelanotide)

Leptin receptor (LEPR) deficiency obesity

Quarterly Sales (Approved)

March 5, 2021 (Est)


Bardet-Biedl syndrome

Phase 3 (Top-line Data)

Late Q4 2020/ Early Q1 2021


Alström syndrome

Phase 3

Recent Posts

See what the community is saying - click to see full post

RYTM - Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) for Patients with Obesity (P

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon